Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples